Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An autosomal recessive, multisystem condition caused by pathogenic variants of the ERCC6 gene, encoding the DNA excision repair protein, ERCC-6. Cockayne spectrum with or without cerebrooculofacioskeletal syndrome is characterized by growth failure at birth, with little or no postnatal neurologic development in addition to congenital cataracts or other structural anomalies of the eye, early postnatal contractures of the spine (kyphosis, scoliosis) and joints, and death usually occurring by age five years. This term lumps Cockayne syndrome type 2/B (CSB), cerebrooculofacioskeletal syndrome 1 (COFS syndrome), and De Sanctis-Cacchione syndrome into a spectrum of disease.
Biomarker and diagnostic research for Cockayne spectrum with or without cerebrooculofacioskeletal syndrome has been reported in the published literature.
No clinical trials have been registered for Cockayne spectrum with or without cerebrooculofacioskeletal syndrome.
13 publications have been identified in PubMed for Cockayne spectrum with or without cerebrooculofacioskeletal syndrome. Research spans Review / Meta-Analysis (36%), Diagnostic / Biomarker (18%), and Case Report / Case Series (18%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 4 | 36% |
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 3:38 PM UTC
Common questions about Cockayne spectrum with or without cerebrooculofacioskeletal syndrome
Testing and diagnosis research |
2 |
18% |
Patient case studies | 2 | 18% |
Laboratory research | 2 | 18% |
Disease patterns and progression | 1 | 9% |
Patel S (2026). [PMID: 41921730](https://pubmed.ncbi.nlm.nih.gov/41921730/). *Dev Biol*. [Review / Meta-Analysis]
El-Dessouky SH (2026). [PMID: 41795876](https://pubmed.ncbi.nlm.nih.gov/41795876/). *Ophthalmic Genet*. [Basic Science / Preclinical]
Bie X (2025). [PMID: 41299792](https://pubmed.ncbi.nlm.nih.gov/41299792/). *Orphanet J Rare Dis*. [Case Report / Case Series]
Natalia GR (2025). [PMID: 41130868](https://pubmed.ncbi.nlm.nih.gov/41130868/). *Parkinsonism Relat Disord*. [Review / Meta-Analysis]
Chen J (2025). [PMID: 40842628](https://pubmed.ncbi.nlm.nih.gov/40842628/). *Front Genet*. [Diagnostic / Biomarker]
Karuntu JS (2025). [PMID: 39733931](https://pubmed.ncbi.nlm.nih.gov/39733931/). *Prog Retin Eye Res*. [Review / Meta-Analysis]
Khorrami M (2025). [PMID: 41459025](https://pubmed.ncbi.nlm.nih.gov/41459025/). *Genet Res (Camb)*. [Basic Science / Preclinical]
Noureldeen MM (2025). [PMID: 40514726](https://pubmed.ncbi.nlm.nih.gov/40514726/). *Ital J Pediatr*. [Epidemiology / Natural History]
He X (2024). [PMID: 39473441](https://pubmed.ncbi.nlm.nih.gov/39473441/). *Front Genet*. [Diagnostic / Biomarker]
Zulfiqar S (2024). [PMID: 35645363](https://pubmed.ncbi.nlm.nih.gov/35645363/). *Int J Neurosci*. [Case Report / Case Series]